← Back to Search

NCX 470 0.1% for Open-Angle Glaucoma (Whistler Trial)

Phase 2 & 3

Recruiting

Research Sponsored by Nicox Ophthalmics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subjects without glaucoma

≥18 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 days

Awards & highlights

Whistler Trial Summary

This trial will test the effects of a medication called NCX 470 on the fluid in the eyes of healthy volunteers or people with high eye pressure. It will compare the medication to a placebo to see

Who is the study for?

This trial is for adults over 18 years old, of any gender, who do not have glaucoma but may have ocular hypertension (OHT) with eye pressure between 16 and 28 mmHg. It's not suitable for people already diagnosed with glaucoma.Check my eligibility

What is being tested?

The study tests NCX 470 ophthalmic solution against a placebo to see how it affects the fluid dynamics in the eyes of healthy volunteers or those with high eye pressure but no glaucoma.See study design

What are the potential side effects?

While specific side effects are not listed here, typical reactions to ophthalmic solutions can include temporary burning sensation, eye irritation or discomfort, watery eyes, and possible allergic reactions.

Whistler Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have glaucoma.

Select...

I am 18 years old or older.

Whistler Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in AHD

Whistler Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: NCX 470 0.1%Active Control1 Intervention

NCX 470 0.1% - one drop in the randomized eye once a day for 8 days

Group II: PlaceboPlacebo Group1 Intervention

Artificial tears - one drop in the randomized eye once a day for 8 days

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Nicox Ophthalmics, Inc.Lead Sponsor

6 Previous Clinical Trials

2,772 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there ongoing efforts to enroll individuals in this research study at the moment?

"As per clinicaltrials.gov, this study is actively seeking individuals to participate. The trial was initially posted on December 12th, 2023 and underwent its most recent revision on January 9th, 2024."

Answered by AI

What is the current number of individuals being admitted into this particular medical trial?

"Indeed, the data available on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible candidates. The initial posting of the trial occurred on December 12th, 2023, and it was most recently updated on January 9th, 2024. For this study, a total of 20 participants will be enrolled from one designated site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

2023. "Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05938699.

All > Glaucoma > Latisse